2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) Cabozantinib 80 MG - RCC, Renal Cell Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 18 | 2023-12-20 | 2026-10-23 |
Carcinoma, Renal Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Breast Diseases (1) · Breast Neoplasms (1)
cabozantinib (1)
A2 Biotherapeutics Inc. (1) · University of Texas Southwestern Medical Center (1)
United States (2)
John Welch, MD, PhD (1) · Tian Zhang, MD (1)